Structural Investigations of the Inhibition of Escherichia coliAmpC β-Lactamase by Diazabicyclooctanes
In: Antimicrobial Agents and Chemotherapy, Jg. 65 (2021-01-20), Heft 2, S. e02073-20- (200205248S.)
Online
serialPeriodical
Zugriff:
β-Lactam antibiotics are presently the most important treatments for infections by pathogenic Escherichia coli, but their use is increasingly compromised by β-lactamases, including the chromosomally encoded class C AmpC serine-β-lactamases (SBLs). The diazabicyclooctane (DBO) avibactam is a potent AmpC inhibitor; the clinical success of avibactam combined with ceftazidime has stimulated efforts to optimize the DBO core.
Titel: |
Structural Investigations of the Inhibition of Escherichia coliAmpC β-Lactamase by Diazabicyclooctanes
|
---|---|
Autor/in / Beteiligte Person: | Lang, Pauline A. ; Leissing, Thomas M. ; Page, Malcolm G. P. ; Schofield, Christopher J. ; Brem, Ju¨rgen |
Link: | |
Zeitschrift: | Antimicrobial Agents and Chemotherapy, Jg. 65 (2021-01-20), Heft 2, S. e02073-20- (200205248S.) |
Veröffentlichung: | 2021 |
Medientyp: | serialPeriodical |
ISSN: | 0066-4804 (print) ; 1098-6596 (print) |
DOI: | 10.1128/AAC.02073-20 |
Sonstiges: |
|